Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q01804
UPID:
OTUD4_HUMAN
Alternative names:
HIV-1-induced protein HIN-1
Alternative UPACC:
Q01804; B4DYS4; Q147U2; Q1ZYK1; Q6PG39; Q96MQ5; Q9NT94; Q9UPV6
Background:
OTU domain-containing protein 4, also known as HIV-1-induced protein HIN-1, plays a crucial role in cellular processes through its deubiquitinase activity. It specifically hydrolyzes the isopeptide bond between ubiquitin and target proteins, regulating inflammatory responses and pathogen recognition in the innate immune system. Its activity is modulated by phosphorylation, influencing the NF-kappa-B pathway by deubiquitinating the MYD88 adapter protein. Beyond its catalytic function, it serves as a scaffold for assembling deubiquitinase-substrate complexes, notably with USP7 and USP9X to stabilize the ALKBH3 enzyme, crucial for repairing alkylated DNA lesions.
Therapeutic significance:
Understanding the role of OTU domain-containing protein 4 could open doors to potential therapeutic strategies.